ALC$79.44
$80.41
Chart
Performance
Key Stats
AI ALC Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAlcon demonstrates strong fundamentals with robust profitability and a healthy balance sheet. While trading slightly above historical valuation multiples, its leading position in the growing eye care market and consistent performance justify a positive outlook. Technical indicators suggest a consolidation phase after a recent upward move, but the long-term trend remains positive.
Thematic
Alcon benefits from several favorable secular trends in the eye care industry, including an aging global population, increasing awareness of eye health, and technological advancements in surgical procedures and vision correction.
Fundamental
Alcon exhibits strong financial health, characterized by solid revenue growth, improving profitability, a healthy balance sheet with manageable debt, and consistent free cash flow generation.
Technical
The stock is trading above key moving averages, indicating a generally bullish trend. However, some oscillators suggest it might be approaching overbought levels, signaling a potential for a short-term pause or minor correction.
| Factor | Score |
|---|---|
| Aging Population | 90 |
| Technological Advancements | 85 |
| Eye Health Awareness | 70 |
| Market Competition | 60 |
| Healthcare Spending | 75 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 85 |
| Growth | 75 |
| Balance Sheet Health | 90 |
| Cash Flow | 88 |
| Dividend Yield | 50 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 40 |
| Volume Confirmation | 70 |
| Support & Resistance | 75 |
| MACD | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Earnings Surprises
The company has consistently surpassed EPS estimates in recent quarters, with surprises ranging from 1.09% to 16.58%, indicating robust operational execution and efficient cost management.
Reasonable P/E Ratio
The trailing P/E ratio of 40.84 is comparable to industry averages, suggesting the stock is not excessively overvalued given its market position and growth prospects.
Bearish Points (7)
High Price-to-Sales Ratio
The Price-to-Sales (P/S) ratio of 6.1 is on the higher side, suggesting that the market is valuing the company's revenue highly, which could be a risk if revenue growth falters.
Mixed EPS Estimates
While recent EPS has been positive, the EPS estimate for Q2 2025 (0.77) is higher than the reported EPS for Q1 2025 (0.72), indicating potential for future misses.
Calendar
May 2025
14
Ex-Dividend Date
May 2025
15
Next Dividend Date
August 2025
20
Next Earnings Date
H: $0.77
A: $0.72
L: $0.68
H: 2.68B
A: 2.66B
L: 2.61B
Profile
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Seasonals
Price Target
105.46 USD
The 39 analysts offering 1 year price forecasts for ALC have a max estimate of 123.00 and a min estimate of 84.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct and primary competitor to Alcon in surgical eye care products (e.g., cataract, vitreoretinal) and vision care (e.g., contact lenses, dry eye solutions). Both companies operate across similar global markets with comparable product portfolios.
Weight: 98
Major diversified healthcare conglomerate with a significant presence in vision care (Acuvue contact lenses) and ophthalmic surgical products (through its Johnson & Johnson Surgical Vision unit, formerly Abbott Medical Optics). Direct competitor to Alcon's core businesses.
Weight: 95
Strong competitor in the vision care segment through its CooperVision division, offering a wide range of contact lenses. Also operates in women's healthcare, but vision care is a direct overlap with Alcon.
Weight: 93
Leading global player in ophthalmic surgical devices, diagnostic equipment for eye care, and microscopy solutions. Directly competes with Alcon in several surgical and diagnostic product categories.